ARO-MUC5AC / Arrowhead - LARVOL DELTA

Study of ARO-MUC5AC in Healthy Subjects and Patients With Muco-Obstructive Lung Disease (clinicaltrials.gov) - P1/2 | N=78 | Terminated | Sponsor: Arrowhead Pharmaceuticals | Phase classification: P1 ➔ P1/2

Phase classification • Asthma • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

Study of ARO-MUC5AC in Healthy Subjects and Patients With Muco-Obstructive Lung Disease (clinicaltrials.gov) - P1 | N=78 | Terminated | Sponsor: Arrowhead Pharmaceuticals | Active, not recruiting ➔ Terminated; Sponsor business decision

Trial termination • Asthma • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

Study of ARO-MUC5AC in Healthy Subjects and Patients With Muco-Obstructive Lung Disease (clinicaltrials.gov) - P1 | N=78 | Active, not recruiting | Sponsor: Arrowhead Pharmaceuticals | Recruiting ➔ Active, not recruiting | Trial completion date: Feb 2025 ➔ Nov 2024 | Trial primary completion date: Feb 2025 ➔ Nov 2024

Enrollment closed • Trial completion date • Trial primary completion date • Asthma • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

Study of ARO-MUC5AC in Healthy Subjects and Patients With Muco-Obstructive Lung Disease (clinicaltrials.gov) - P1 | N=104 | Recruiting | Sponsor: Arrowhead Pharmaceuticals | Trial completion date: Nov 2024 ➔ Feb 2025 | Trial primary completion date: Nov 2024 ➔ Feb 2025

Trial completion date • Trial primary completion date • Asthma • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

Study of ARO-MUC5AC in Healthy Subjects and Patients With Muco-Obstructive Lung Disease (clinicaltrials.gov) - P1 | N=104 | Recruiting | Sponsor: Arrowhead Pharmaceuticals | Phase classification: P1/2 ➔ P1 | Trial completion date: Feb 2024 ➔ Nov 2024 | Trial primary completion date: Dec 2023 ➔ Nov 2024

Phase classification • Trial completion date • Trial primary completion date • Asthma • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

Study of ARO-MUC5AC in Healthy Subjects and Patients With Muco-Obstructive Lung Disease (clinicaltrials.gov) - P1/2 | N=104 | Recruiting | Sponsor: Arrowhead Pharmaceuticals | N=58 ➔ 104 | Trial completion date: Apr 2023 ➔ Feb 2024 | Trial primary completion date: Apr 2023 ➔ Dec 2023

Enrollment change • Trial completion date • Trial primary completion date • Asthma • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases • MUC5AC

ARWR: Interim Data for Phase 1/2 Trial of ARO-RAGE Shows Potential for Pulmonary TRiM Platform… (Yahoo Finance) - "Update on Early Development Programs: ARO-MUC5AC....Arrowhead is currently conducting a Phase 1/2 trial similar in design to the ARO-RAGE trial and enrollment of the asthma patient cohort has commenced."

Enrollment status • Asthma • Respiratory Diseases

"$ARWR Arrowhead Pharmaceuticals Initiates Phase 1/2a Studies for Two Pulmonary Candidates ARO-MUC5AC and ARO-RAGE https://t.co/DHMgmxRnaq" (@stock_titan)

MUC5AC

Study of ARO-MUC5AC in Healthy Subjects and Patients With Asthma (clinicaltrials.gov) - P1/2 | N=58 | Recruiting | Sponsor: Arrowhead Pharmaceuticals | Not yet recruiting ➔ Recruiting

Enrollment open • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases • MUC5AC

Silencing Muc5ac Expression with a Lung-Targeted RNAi Trigger Prevents Allergen-Induced Mucoobstruction and Airway Hyperresponsiveness (ATS 2022) - "After establishing baseline carbachol response, sheep were challenged with inhaled Ascaris suum extract and lung mechanics recorded for 8 hours; airway hyperresponsiveness was assessed by measuring carbachol response 24 hours post-challenge. Epithelial-targeted RNAi trigger conjugates effectively silence allergen-induced Muc5ac expression and significantly reduce adverse responses in airway mechanics, confirming the importance of this inducible mucin in airway obstruction. ARO-MUC5AC (ADS-013) is a promising new therapeutic candidate for the treatment of severe asthma and other mucoobstructive lung diseases."

Asthma • Immunology • Inflammation • Pulmonary Disease • Respiratory Diseases • IL13 • MUC5AC

Study of ARO-MUC5AC in Healthy Subjects and Patients With Asthma (clinicaltrials.gov) - P1/2 | N=58 | Not yet recruiting | Sponsor: Arrowhead Pharmaceuticals

New P1/2 trial • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases • MUC5AC